NRSN · NeuroSense Therapeutics Ltd
United States · RS rating 88 · As of 2026-10-14
| Price | 3.06 USD |
|---|---|
| 1-day change | -12.3% |
| RS rating (overall / 1M / 3M / 12M) | 88 / 2 / 98 / 97 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 36 / 51 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +58.6% |
| Market cap (USD) | $25.3M |